Editors' ChoiceCancer

Effective to the Bone

See allHide authors and affiliations

Sci. Signal.  09 Sep 2014:
Vol. 7, Issue 342, pp. ec248
DOI: 10.1126/scisignal.2005880

Bone is the most common site of metastatic spread for prostate cancer, and tumors that have spread to the bone are usually very difficult to treat. Dovitinib is a recently developed drug that inhibits the fibroblast growth factor receptor. Now, Wan et al. have demonstrated that dovitinib is effective for some patients with prostate cancer that has spread to bone. The authors also identified an explanation for some of the observed antitumor effects by showing that the drug interferes with interactions between the prostate cancer cells and surrounding stromal cells in the bone microenvironment.

X. Wan, P. G. Corn, J. Yang, N. Palanisamy, M. W. Starbuck, E. Efstathiou, E. M. L.-N. Tapia, A. J. Zurita, A. Aparicio, M. K. Ravoori, E. S. Vazquez, D. R. Robinson, Y.-M. Wu, X. Cao, M. K. Iyer, W. McKeehan, V. Kundra, F. Wang, P. Troncoso, A. M. Chinnaiyan, C. J. Logothetis, N. M. Navone, Prostate cancer cell–stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci. Transl. Med. 6, 252ra122 (2014). [Abstract]